Novel applications for Ex-vivo PDX models of the Tumor Microenvironment

Logo
Presented by

Veronica Sacchi, PhD, Scientist III, PhenoVista Biosciences

About this talk

Ex-vivo platforms are useful to gain data regarding the efficacy of an oncology treatment throughout the course and after completion of a study. Furthermore, ex-vivo assays can be used to unravel mechanisms of action for immuno-oncology agents and assess cytotoxicity of oncology therapeutics. In this webinar, case studies will be discussed to demonstrate physiologically relevant 2D and 3D ex vivo PDX Models for testing oncologic therapeutic agents. Register for this webinar to learn: • How to combine physiologically relevant 2D and 3D ex vivo PDX models with quantitative fluorescence imaging and luminescence assays to determine efficacy of oncology treatments. • The advantages of using tumor fragments vs. other 3D systems. • How incorporating a diversity of readouts, including industry standard CellTiter Glow and fluorescence microscopy, can provide comprehensive insights to drive oncology research programs forward. • How adapting different experimental parameters, i.e. drug combinations and treatment length (3 days to 21-day assays), as well as the readouts (RNA/Protein isolation) can improve richness of data we can obtain from a study.

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (37)
Subscribers (2414)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.